Click Here to return To Results

 

One-Year Sustained Efficacy of Erenumab in Episodic Migraine Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020 See this aricle in Pubmed Article Abstract Over 52 weeks, erenumab provided sustained efficacy in episodic migraine; the safety profiles were similar between erenumab dose groups in the presence of dose blinding.

Related Tags

(click to filter results - removes previous filter) calcitonin gene-related peptide receptor blocker efficacy erenumab migraine migraine,treatment of monoclonal antibodies treatment of neurologic disorder

Click Here to return To Results